¹⁸F-positron-emitting/fluorescent labeled erythrocytes allow imaging of internal hemorrhage in a murine intracranial hemorrhage model

Abstract

An agent for visualizing cells by positron emission tomography is described and used to label red blood cells. The labeled red blood cells are injected systemically so that intracranial hemorrhage can be visualized by positron emission tomography (PET). Red blood cells are labeled with 0.3 mg of a positron-emitting, fluorescent multimodal imaging probe, and used to non-invasively image cryolesion induced intracranial hemorrhage in a murine model (BALB/c, 2.36 Â 10 8 cells, 100 mCi, <4 mm hemorrhage). Intracranial hemorrhage is confirmed by histology, fluorescence, bright-field, and PET ex vivo imaging. The low required activity, minimal mass, and high resolution of this technique make this strategy an attractive alternative for imaging intracranial hemorrhage. PET is one solution to a spectrum of issues that complicate single photon emission computed tomography (SPECT). For this reason, this application serves as a PET alternative to [ 99m Tc]-agents, and SPECT technology that is used in 2 million annual medical procedures. PET contrast is also superior to gadolinium and iodide contrast angiography for its lack of clinical contraindications.

Recent developments in multimodality fluorescence imaging probes

“…Currently, most OFI/PET dual-modality probes are developed for use in oncology because of their potential translation to clinic in cancer diagnosing, staging and therapy monitoring ( Supplementary Information Table S5 ) 77 . Other biomedical research fields including brown adipose tissues 91 , intracranial hemorrhage and damage 93 , 94 , myocardial perfusion 95 , 96 and Alzheimer's disease 97 have also considered dual-modal probe use in their preclinical studies in order to unravel or track the physiological or pathological changes inside the body. With both the upsurge in development of synthetic labelling methodology and the expansion of biomedical applications, we expect advancement of use of the dual-modality OFI/PET probe in translational medicine in the near future.…”

Fluorine‐18 Radiolabelling and Photophysical Characteristics of Multimodal PET–Fluorescence Molecular Probes

“… Top) Design of a Cy3 hydrocyanine dye (red) complexed to a fluorine‐18 labelled trifluoroborate salt and NHS ester ( 32 ) by Wang et al., which allowed for bioconjugation to the terminal amino group of lysine residues present on the surface of red blood cells [47] . The resulting PET–fluorescence labelled red blood cells were subsequently used to image intracranial haemorrhages.…”

Convection Enhanced Delivery for Diffuse Intrinsic Pontine Glioma: Review of a Single Institution Experience

“…Nonetheless, recent developments in synthetic radiochemistry have expanded the library of compounds that can be modified and transformed into theranostics, maintaining the original compound’s bioactivity. For instance, we have experience in generating [ 124 I]- and [ 18 F]-labeled agents [ 74 , 75 , 76 , 77 , 78 , 79 , 80 ]. Of note, the isotope conjugated with the molecule will have great impact on its fate and clinical applicability.…”